Johannes Streffer, Prof. MD PhD

JAD profile

Affiliation(s): 

Janssen Research and Development; a division of Janssen Pharmaceutica N.V. (Beerse; Belgium); Reference Center for Biological Markers of Dementia (BIODEM); Institute Born-Bunge; University of Antwerp; Institute Born-Bunge and University of Antwerp

Areas of Interest: 

Alzheimer disease, Biochemical Biomarker, disease modifying therapy clinical trials, Clinical trials of MCI and AD

Biography & Research: 

Johannes earned his Medical Degree from the University of Tubingen, Germany in 1994. He is board certified in Psychiatry and Neurology. After graduation he conducted basic research in neuro-oncology as well as coordinating clinical research activities with a neuro-oncologic focus in the neurologic university hospital in Tubingen, parallel to his training in general Neurology. January 2000, Department of Psychiatry Research (PUK Zurich). Coordination of the geronto-psychatric outpatient and specialized memory clinic; Clinical research activities, focusing on early experimental AD trials, including biomarker modalities as PET, volumetric and functional MRI, genetics, cognition and CSF markers. 2007 Janssen R&D, Experimental Medicine with clinical programs in MS, ICP, PD, AD and assuming increasing responsibilities including the position of CSF biomarker group leader supporting the bapineuzumab LD (2011-2014), AD strategy leader (2012-2013) and member of the Alzheimer Disease Area Leadership team (2013 ongoing). Since 2012 he is clinical leader of the Janssen BACEi program, targeting disease interception in early Alzheimer’s Disease and transitioned with this program into late development in 2015. Additional to the compound related activities he has initiated a number of methodological and biomarker studies, focusing on early diagnosis and trial methodology. 2012/2014 he was member of the JRD R&D Diversity and Inclusion Council. Currently he is industry lead for EMIF-AD, part of the IMI-EMIF (5 year project, 2013 – 2017; 56 partners; 14 European countries represented; 56MM € worth of resources; “3 projects in one”), that integrates a wide variety of AD data cohorts, biomarker rich single center cohorts to EHRs, to foster the understanding of early markers and change in the predementia AD spectrum. Since 09/2015 Johannes is Visiting Professor, Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp. Research Interest - Alzheimer's disease and neurodegeneration with a special focus on Clinical trials and Biomarkers